Study guide
14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
Key Takeaways Explain This Topic AI
Histologies 9590–9993 with behavior /3 are reportable; /1 heme histologies such as in situ follicular or mantle cell neoplasia are not reportable in the U.S., and for heme reportability "consistent with" counts as a definitive diagnosis.
Heme rule M2: a single histology is always a single primary, whatever the timing or site, and bilateral involvement is one primary; the exception is nodal plus extranodal MALT lymphoma (9699/3), which is two primaries.
A chronic and an acute neoplasm diagnosed in the initial clinical workup with one biopsy are a single primary coded to the acute neoplasm (M8), but two biopsies make them multiple primaries (M11).
A chronic neoplasm followed by an acute transformation after the initial workup is multiple primaries (M10); acute followed by chronic is a single primary without treatment (M12) and multiple primaries after treatment (M13).
Leukemias, MDS, MPNs and other marrow diseases are always coded to bone marrow C421; lymphoma in several lymph node regions is coded C778; the Heme DB Multiple Primaries Calculator is used only when rules M1–M14 do not apply (M15).
Last updated: September 2026
The tools
Tool Use
Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual Reportability, multiple primary (M) rules, primary site and histology (PH) rules, and grade and staging notes
Hematopoietic Database (Heme DB) One page per histology: reportability status, ICD-O code and valid years, synonyms, definitive diagnostic methods , immunophenotype and genetics, transformations to and from , treatment, grade, primary site notes, and the Multiple Primaries Calculator
The Heme DB is built from the WHO classification of haematolymphoid tumours (5th edition) . It now also lists the corresponding ICD-O-4 codes for learning purposes. Registries still code with ICD-O-3.2 and the Heme DB.
Reportability
Search the Heme DB "Reportable" field. It covers every term in the current WHO book, including non-reportable terms and terms without an ICD-O code.
Report morphology 9590–9993 with behavior /3 .
/1 heme histologies are not reportable in the U.S. This includes in situ lymphomas such as in situ follicular neoplasia (9695/1) and in situ mantle cell neoplasia (9673/1), for any year. Myeloid precursor lesions such as clonal hematopoiesis are not reportable.
Exception: a /1 heme neoplasm that a physician calls malignant is reported with behavior changed to /3 under the matrix rule.
"Consistent with" is definitive for heme reportability and casefinding. It was removed from the ambiguous-terms list because pathologists commonly use it for heme diagnoses.
The ambiguous terms apparently, appears, comparable with, compatible with, favor(s), malignant appearing, most likely, presumed, probable, suspect(ed), suspicious (for) and typical (of) also make a heme case reportable. Ambiguous cytology alone is not reportable.
Follow-back to the physician is recommended, because heme cases are often diagnosed outside the hospital and are otherwise underreported.
Multiple primary rules (M1–M15)
- Rule Outcome Situation
- M1 Single Minimal information (DCO, pathology report only)
M2 Single Single histology. Recurrence of the same histology is always the same primary, timing and site do not matter , and bilateral involvement is one primary. Exception: nodal MALT (C77x, 9699/3) before or after extranodal MALT is two primaries. Follicular lymphomas (9690, 9691, 9695, 9698) are always the same primary; update the histology to the higher grade. Therapy-related myeloid neoplasm is one primary coded 9920/3
M3 Single Myeloid sarcoma with or after AML, or mast cell sarcoma with or after mast cell leukemia (a manifestation of the leukemia). Does not apply to CML
M4 Single Two or more B-cell non-Hodgkin lymphomas in the same specimen (not cutaneous lymphomas)
M5 Single Hodgkin and B-cell non-Hodgkin lymphoma in the same location at the same time, during the initial workup
M6 Multiple Hodgkin in one location and non-Hodgkin lymphoma in a different location
M7 Single A more specific histology after an NOS , when the Multiple Primaries Calculator confirms they are the same primary. Update the original histology if the code was valid in that diagnosis year
M8 Single (code the acute ) Chronic and acute neoplasm diagnosed during the initial clinical workup with one positive biopsy
- M9 Single (acute) Chronic and acute in the initial workup, no biopsy documentation (rarely used)
- M10 Multiple Chronic neoplasm first, then an acute neoplasm diagnosed after the initial workup is completed
- M11 Multiple Chronic and acute in the initial workup with two biopsies, one confirming each
M12 Single Acute first, then reverts to a related chronic neoplasm after the workup, with no treatment (or treatment unknown)
M13 Multiple Acute first, then a chronic neoplasm after treatment of the acute one, even if treatment was not finished
M14 Single PTLD diagnosed in the same report with a B-cell, T-cell or Hodgkin lymphoma or plasmacytoma/myeloma. Code the accompanying lymphoma
- M15 Calculator None of M1–M14 applies: use the Heme DB Multiple Primaries Calculator
- The chronic/acute rules (M8–M13)
They apply only when the Heme DB lists the two diseases as "transformations to" or "transformations from" each other. Otherwise go to M14 and M15.
The phrase "initial clinical workup" replaced the old 21-day window.
Examples:
MDS diagnosed in 2019 and AML in 2024: M10 gives two primaries .
CLL/SLL followed later by diffuse large B-cell lymphoma (Richter transformation), after the initial workup: M10 gives two primaries .
A lymph node biopsy showing DLBCL and follicular lymphoma together is one specimen with two B-cell lymphomas. M4 gives one primary , and PH11 codes it as DLBCL .
Never go straight to the calculator. Use it only when the rules send you there.
Primary site (PH rules)
- Situation Primary site
- Leukemias, MDS, MPNs and other bone marrow diseases Always C421 (bone marrow)
- Only a positive peripheral blood smear C421
- Plasma cell myeloma C421
- Plasmacytoma The bone (PH3) or extraosseous site (PH2) involved
- CLL/SLL with marrow or blood involvement C421 (PH5), whatever the node or organ involvement
- CLL/SLL without marrow or blood involvement, or unknown The involved nodes, organ or tissue (PH6)
- Lymphoma in one lymph node chain or region That region (C770–C775)
- Lymphoma in multiple lymph node regions C778 , unless a physician documents a specific region of origin (rare)
Lymphoma in an organ only, or an organ with its regional nodes The organ , for example stomach C16x for gastric MALT lymphoma
AML with myeloid sarcoma Follow the Module 5 rules (PH10)
Bone marrow involvement by a lymphoma does not make C421 the primary site. For example, DLBCL in several node regions with a positive marrow is coded C778 , and the marrow involvement is recorded in staging and the metastasis items.
Histology (PH rules) highlights
PH11: DLBCL with any other non-Hodgkin lymphoma in the same site: code DLBCL (9680/3) .
PH14: B-cell non-Hodgkin and Hodgkin lymphoma together in the same node or node regions (the M5 situation): code 9596/3 , composite Hodgkin and non-Hodgkin B-cell lymphoma.
NOS versus specific (PH28–PH29): code the specific histology identified by the definitive diagnostic method in the Heme DB.
PH31 , the last resort: code the numerically higher ICD-O code.
Other heme coding points
Grade: Grade Clinical and Grade Pathological are coded 8 , and the post-therapy grades are blank (Section 13.4).
Diagnostic Confirmation 3: positive histology plus immunophenotyping or genetic testing (Section 10.3).
Staging: lymphomas use the AJCC Hodgkin and non-Hodgkin lymphoma chapters (Lugano) and Summary Stage rules. Leukemias are Summary Stage 7 (systemic).